Rosetta Genomics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

rosettagenomics.com

Stage

Dead | Dead

About Rosetta Genomics

Rosetta Genomics (NASDAQ: ROSG) is a molecular diagnostics company advancing microRNA-based diagnostics discovered and developed through its proprietary microRNAs and platform technologies. Backed by a strong IP portfolio, Rosetta Genomics' scientists have developed proprietary platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types. These technologies enable the identification and advancement of multiple diagnostic projects addressing critical unmet needs in cancer, cardiovascular diseases and other indications. The Company's four commercial oncology tests have been launched in multiple countries worldwide via partners, and by a Company-led effort in the U.S.

Rosetta Genomics Headquarter Location

10 Plaut St.

Rehovot, 76706,

Israel

732-246-9900

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Rosetta Genomics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Rosetta Genomics is included in 2 Expert Collections, including Cancer.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Rosetta Genomics Patents

Rosetta Genomics has filed 83 patents.

The 3 most popular patent topics include:

  • RNA
  • MicroRNA
  • MicroRNA precursor families
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/4/2016

7/28/2020

Molecular biology, Membrane biology, Biotechnology, Dosage forms, Protein domains

Grant

Application Date

2/4/2016

Grant Date

7/28/2020

Title

Related Topics

Molecular biology, Membrane biology, Biotechnology, Dosage forms, Protein domains

Status

Grant

Latest Rosetta Genomics News

Drug discovery on a chip - and no mice

Jan 17, 2022

Drug discovery on a chip - and no mice Dr. Isaac Bentwich reveals Quris, which aims to save pharmaceutical companies hundreds of millions of dollars and years of development. In the early 2000s, Israel had a number of drug development companies that were ahead of their time. Compugen and Rosetta Genomics developed systems for computerized drug discovery and design, what would today be called big data and artificial intelligence. At that time, however, AI was considered science fiction, and the term "big data" hadn’t yet been invented. Rosetta Genomics, founded by Dr. Isaac "Tzachon" Bentwich, on the basis of his father Zvi's research, was a huge scientific success when it discovered a large amount of "junk DNA", that is, DNA whose purpose was unclear at the time. It gradually became clear, however, that this DNA actually managed many physiological processes, including control over other genes. Rosetta patented all these gene sequences, but despite its tremendous scientific achievement, and despite going public on Nasdaq, it was not a commercial success, and was eventually sold for $10 million. Now Bentwich is back with a new company, Quris, and an equally exciting and innovative vision for drug development using artificial intelligence. "Rosetta was ahead of its time," Bentwich said in an interview with "Globes". "With Quris, our emphasis today is to do things that are ahead of their time, but also to be practical." Quris was officially founded in early 2020 by Bentwich and Yossi Haran, raising $9 million from leading investors like Kobi Richter, Matthew Bronfman, Moshe Yanai and Rami Unger. Some very impressive names are involved in the company: Nobel Laureate Aharon Ciechanover is the scientific leader; Prof. Bob Langer of MIT, a biomedical engineering guru and a co-founder of Moderna, is on the scientific advisory board. "This group was also with me at Rosetta Genomics; they are a highly respected group of scientists." A $19 million funding round Quris announced last week that it had raised $19 million, one of the biggest seed rounds for a biomed company. The round was led by Welltech Ventures, along with iAngels, GlenRock Capital and private investors. "I'm a doctor by training, but I’ve been an entrepreneur for many years. Quris is my fourth company," says Bentwich, who approaches life sciences, information technology and artificial intelligence from several different directions. "But only now are we starting to crack one of the hardest nuts. The problem can be defined in one sentence, but it’s the key to a huge leap forward and huge financial savings in drug development: the ability to predict which molecule will be effective and safe in the human body. That's the biggest unsolved problem, and that's all that we’re dealing with." Bentwich points out that artificial intelligence can benefit drug development in a number of ways, with each company making its contribution, and together bringing about a revolution. Over the past few years, some of have already raised hundreds of millions of dollars at very high valuations. "All of these companies are making improvements in drug discovery, but after they quickly and efficiently discover new candidates - how do they test them? These days, in cell cultures. A drug that appears effective in culture is then tested in mice. This is not a good method. It costs lots of money, and doesn’t provide a successful prediction - maybe only two drugs that are successful in mice will also pass human trials successfully. Suppose someone told you, ‘We’re going to build ten skyscrapers. Eight will collapse and you’ll live in whatever is left standing.'" Miniaturized human components So, what does Quris do? "There are three components to the solution. One is a technology that’s come of age during the last two years; it’s called organ-on-a-chip (OOC). You can simulate 3-D organs that contain most of the components of a human organ, but are tiny, perhaps three millimeters in size. Tiny liver, really miniature brain. Of course, it's not a brain that thinks thoughts, but it simulates the relationships between the various cells of the brain far better than cell culture, and better than a mouse. "We're improving this technology by producing a platform we call 'Patients-on-a-Chip', meaning we connect a number of organs-on-a-chip together. We essentially create a small-scale 'blood circulation' system that connects, let’s say, to a miniaturized kidney with a miniaturized liver. Then when we apply the drug to the organs, the liver breaks it down, and the kidney secretes it, and you can really simulate how it will function in the body, be broken down and eliminated, and from there, predict its effectiveness and its toxicity." But creating one organ-on-a-chip, Bentwich says, is like testing a drug in a single-patient clinical trial. "It's already better than a mouse, but we want more people. So, we've formed an exclusive strategic partnership with the New York Stem Cell Foundation that allows us to produce many miniaturized organs from stem cells which represent many different types of people. "The third component of our technology, which is where we’re really different, is the artificial intelligence component. Suppose we know a thousand drugs exist that are known to be safe, and another thousand drugs that are known to be unsafe, and we run them through our Patients-on-a-Chip, with its genetic diversity. Perhaps we could get an artificial intelligence system that begins to know what an unsafe drug looks like, and what a safe drug looks like. The artificial intelligence would differentiate between them, and understand what sets the safe ones apart in their molecular structure. That’s essentially the future we’re setting our sights on. " Where do you obtain data about drugs that have failed or succeeded? "At first, from previous clinical trials. For example, there is a list of 1,028 drugs that are unsafe to use due to liver toxicity. In the future, we hope to establish strategic collaborations with pharma companies which will tell us about drugs that have failed, and maybe about things that haven’t been fully reported. We’re currently in discussions about collaborations with one of the top five pharma companies, and with another that’s also in the top 20. We’re hoping the first collaboration agreement will be signed soon, and if so, it will include an $15 million option for the exclusive use of our technology to research safety only, of just one drug, for five years. So, even before we’ve really set out, one of the largest companies in the world says this technology is worth taking an option on." A savings for pharma companies How do you build a business model around this sort of technology? Mainly through collaboration, or your own drug development, too? "Collaboration with pharma companies is a very clear business model. Pharma companies today lose $ 100-700 million per drug in the development process, just because of safety issues. We tell them, you’ll pay $60 million but you’ll save $700 million. We believe that $60-100 million is the appropriate price per drug, and there are a lot of drugs. "But our real emphasis is on our own products, which we may collaborate on later. We have two development programs already started. One is for Fragile X syndrome (a genetic disorder characterized by cognitive impairment). Among rare diseases, it’s one of the most common. Giants like Novartis and Roche have tried to develop treatments for it but without success. This disease has no parallel model in mice, making drug development for it very difficult. "We acquired the rights to develop a drug discovered by Prof. Nissim Benvenisty of the Hebrew University of Jerusalem, who is a world leader in the development of stem cell-based disease models. Our system optimizes the drug. All companies working in AI-driven drug development also develop proprietary drugs. Although it requires a very large investment and a completely different company structure, compared with being a service company only, that's where the big profit potential lies." Will the process of all the AI companies developing drugs simultaneously lead to a revolution whose impact we, the potential patients, will feel? "It will be an earthquake. That’s what I believe, and analysts covering this sector believe it, too. Drugs will be developed at investments of tens rather than hundreds of millions of dollars, and the development time will be much shorter. Many more products will get to market as fast as the Covid-19 vaccine did." The company is currently located in Israel and Boston. Artificial intelligence activity takes place in Israel, while biological activity is in Boston. "To date, Israeli biomed companies have transferred only their marketing activity to the US. Apparently, that’s not enough for a relatively early-stage company to form really good relationships with people from big pharma companies, who meet up at neighborhood cafes in Boston and at scientific conferences. The price we pay is managing development in two countries, to the point where we will control a pipetting robot in the Boston lab from here, or Boston can look through a microscope located in Tel Aviv. We’re experiencing things in this area that are truly cutting edge." Published by Globes, Israel business news - en.globes.co.il - on January 17, 2022. © Copyright of Globes Publisher Itonut (1983) Ltd., 2022.

  • Where is Rosetta Genomics's headquarters?

    Rosetta Genomics's headquarters is located at 10 Plaut St., Rehovot.

  • What is Rosetta Genomics's latest funding round?

    Rosetta Genomics's latest funding round is Dead.

  • Who are the investors of Rosetta Genomics?

    Investors of Rosetta Genomics include GlenRock Israel.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.